FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [ FATE ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
EPSTEIN ROBERT S						111111			<u></u> [			X Directo	r		10% Ow	ner		
C/O FATE THERAPEUTICS, INC.;					3. Date of Earliest Transaction (Month/Day/Year) 05/03/2019							Officer below)	(give title		Other (specifical of the other	pecify		
3535 GENERAL ATOMICS COURT, SUITE 200					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street) SAN DIEGO CA 92121			92121									Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution Date,			Code (Instr.   5)		ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F	s Formally (D) of ollowing (I) (In		Direct Condinect Extr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date if any (Month/Day/Ye	Code (Instr				6. Date Exerc Expiration Da (Month/Day/\	ate	7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$17.15	05/03/2019		A		16,000		(1)	05/03/2029	Common Stock	16,000	(2)	16,000		D			

## **Explanation of Responses:**

1. The shares subject to this option shall vest and become exercisable on the earlier of (i) May 3, 2020 or (ii) the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors.

2. Not applicable.

## Remarks:

/s/ Cindy R. Tahl, as Attorney-

05/07/2019

in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.